BOSTON, July 27, 2017 /PRNewswire/ -- Juniper
Pharmaceuticals (Nasdaq: JNP) ("Juniper" or the "Company"), will
hold a conference call on August 3,
2017, to discuss the financial results for the second
quarter ended June 30, 2017, as
follows:
Date:
Thursday, August 3, 2017
Time:
4:30 p.m.
Dial-in numbers: Toll free: (1-866-374-4635) (U.S.),
(1-855-669-9657) (Canada),
or International: (1-412-902-4218)
Audio webcast (live & archive): www.juniperpharma.com, under
'Investors' or click here.
The teleconference replay will be available approximately one
hour after completion through Thursday,
August 10, 2017, at 1-877-344-7529 (U.S.), 1-855-669-9658
(Canada) or 1-412-317-0088
(International). The replay access code is 10110526.
The archived webcast will be available for one year via the
aforementioned URLs.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing
therapeutics that address unmet medical needs in women's health.
The Company is advancing a pipeline of proprietary product
candidates that leverage its differentiated intravaginal ring
technology and when appropriate the 505(b)(2) regulatory pathway.
Targeted product development investments are enabled by Juniper's
core operating business: the Crinone® (progesterone gel)
franchise and Juniper Pharma Services, which provides high-end
fee-for-service pharmaceutical development and clinical trials
manufacturing to clients. Please visit www.juniperpharma.com for
more information.
Juniper Pharmaceuticals™ is a trademark of Juniper
Pharmaceuticals, Inc., in the U.S. and EU.
Crinone® is a registered trademark of Merck KGaA,
Darmstadt, Germany, outside the
U.S. and of Allergan, Inc. in the U.S.
Investor Contact:
Laura Perry or Heather
Savelle
Argot Partners
212-600-1902
laura@argotpartners.com
heather@argotpartners.com
To receive Juniper's press releases, SEC filings or calendar
alerts by email click here.
Follow us on LinkedIn
View original
content:http://www.prnewswire.com/news-releases/juniper-pharmaceuticals-to-report-second-quarter-2017-results-on-august-3-2017-300495486.html
SOURCE Juniper Pharmaceuticals, Inc.